本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SINGAPORE, Nov. 23, 2023 /PRNewswire/ -- CrimsonLogic, a leader in digital trade facilitation solutions and a member of the PSA Group, has announced that from 1 January 2024, the company's wholly-owned subsidiary, Global eTrade Services (GeTS) will operate under the CrimsonLogic brand. This strategic move consolidates and strengthens its position within the global trade and supply chain landscape. Established in 2016, GeTS has primarily focused on trade compliance services, offering customs clearance solutions such as "TradeWeb" for Singapore, Importer of Records, Business Process Outsourcing services, and a comprehensive suite of digital logistics solutions. With over 35 years of experience worldwide, CrimsonLogic specializes in technology-enablement in the fields of trade facilitation & compliance, port operations, government services and logistics. With over 60 projects implemented across 40 countries, the company's "Total Trade'' suite of solutions facilitates the end-to-end value chain for global trade across governments and business segments. The change is a strategic step to empower partners and customers to leverage the full spectrum of the company's digital capabilities and its expansive global network. "By aligning our capabilities and solutions under one brand, we ensure a clear and accurate representation of our Total Trade vision," said Lawrence Ng, CEO of CrimsonLogic. "We look forward to further strengthening our value proposition and market presence through this brand consolidation, delivering the full range of capabilities offered by our Total Trade suite of solutions to the Asia Pacific region." With a global footprint in over 40 countries, CrimsonLogic has a significant presence in the Asia Pacific region. Ernest Low, Vice President of Asia Pacific at CrimsonLogic, affirmed the significance of this brand consolidation. "This change is a strategic step that allows us to leverage the combined expertise of CrimsonLogic and GeTS, offering a wide range of global trade and supply chain solutions tailored to meet the needs of our Asia Pacific customers, especially for those looking to enter the diverse ASEAN market. Through this change, we deliver value-added, comprehensive capabilities, and a seamless experience for businesses navigating the complex landscape of trade into and out of the Asia Pacific region." About CrimsonLogic CrimsonLogic, part of the PSA Group, is a global technology company driven by innovation to digitalize and simplify global trade. With over 35 years of experience worldwide, CrimsonLogic specializes in technology-enablement in the fields of trade facilitation & compliance, port operations, government services and logistics. As a trusted partner to businesses, logistics service providers and governments, their tailored solutions are designed to meet the unique needs of every client, enabling seamless and secure optimization of supply chains and operations. Having pioneered the world's first single window trade facilitation system for Singapore, CrimsonLogic continues to drive digital transformation in global trade via cutting-edge technology, exemplified by the successful implementation of innovation solutions in over 40 countries worldwide. www.crimsonlogic.com
Up to P1 Million cash credits await new UnionBank Elite and Access clients PASIG, Philippines, Nov. 23, 2023 /PRNewswire/ -- Union Bank of the Philippines (UnionBank) recently launched two new wealth programs, UnionBank Elite and UnionBank Access, as part of the Aboitiz-led bank's commitment to provide an elevated wealth management experience for its valued clients. Elevate your wealth to unbelievable heights with UnionBank Harnessing the strengths of its acquired Citi Wealth business, the two newly unveiled wealth programs bring together time-tested propositions, and even making it better with innovative wealth management approaches from UnionBank. UnionBank Elite, the new premier wealth segment, offers elevated wealth management service to customers with its top-notch propositions. Elite customers are not only guided by a team of wealth management experts with proven track record and experience in investment and financial planning, they are also able to get exclusive access to more local and international investment options to match their need for diversification. Curated experiences and benefits, as well as first dibs to new releases and exclusive events, also await Elite customers. To start the roster of exciting offers, new Elite customers can get up to P1 Million cash credits if they open an account until December 31, 2023. Therese Chan, UnionBank Wealth and Brokerage Head and Board Director of UnionBank Financial Services and Insurance Brokerage Inc. (UFSI), shared "We have also enhanced our wealth program for the emerging affluent, keeping in mind the children of our clients who may be in the process of creating their own wealth," in reference to UnionBank Access, which was also launched to target the next generation of wealth builders. For the ultra-wealthy segment, UnionBank Private Banking continues to champion discretionary wealth management and succession planning for families. The UnionBank Wealth Management movers and shakers at the Manila launch of the program. (From Left to Right: Ramon Melchor Tejero, UFSI President and CEO, Dennis Omila, UB Chief Technology and Operations Officer; Edwin R. Bautista, UB President and CEO; Josiah Go, UB Board Director; Manuel Escueta, UB and UFSI Board Director; Manuel Lozano, UB Chief Financial Officer and UFSI Board Director; Therese Chan, UB Wealth and Brokerage Head and UFSI Board Director; Joyce Gonzalez, UB Retail Banking Head; Albert Cuadrante, UB Chief Marketing Officer; Johnson Sia, UB Treasurer and Global Markets Head; Eric Lustre, UB Chief Trust Executive) As a thought leader in expert wealth advisory, UnionBank also held its Market Outlook event for the second half of the year. This facilitated relevant discussions and offered invaluable and actionable insights on current issues and trends in the Asian and Global markets. Special focus was given to artificial intelligence and megatrends, and the investment opportunities these offer. Anthony Kruger, Director, CAIA, and APAC Head of Platform Strategy at BlackRock, and Jason Lim, Director of Retail Distribution (Southeast Asia) at Allianz Global Investors, led the two-day market event as speakers. BlackRock and Allianz Global Investors are among UFSI's fund house partners. UFSI President and CEO Ramon Melchor Tejero led the celebratory toasts that concluded the event, "To the future that awaits us, filled with innovation and exciting possibilities. And to our exceptional clients, thank you for your loyalty and support that have propelled us forward. Here's to redefining wealth management with UnionBank." To learn more about UnionBank Elite and UnionBank Access, visit www.unionbankph.com/wealth/elite and www.unionbankph.com/wealth/access.
SINGAPORE, Nov. 23, 2023 /PRNewswire/ -- On November 17, 2023, the "TradFi and DeFi Unite: From Asia Pacific to the World" APRTP Summit was successfully held at the Sands Expo & Convention Centre in Singapore. The event, co-hosted by ChainUp, SGTOX, and Alibaba Cloud, drew experts from prominent businesses and institutions from Singapore and the surrounding regions. Establishment of Asia Pacific Real World Asset Platform by The 17 Founding Members of The “Asia Pacific RWA Tokenization Platform” (APRTP) The summit's highlight was the joint announcement by the 17 founding members of the "Asia Pacific RWA Tokenization Platform" (APRTP) of the organization's establishment, followed by a collective inaugural conference. Discussing the significance of real world asset tokenization, Mr. Nathan Ma, Chairman of the Board at SGTOX, underscored its impact within the FinTech and Web3.0 sectors. He spotlighted international success stories, including MakerDao's tokenization of $5 billion in bonds, the Hong Kong government's issuance of HK$760 million in green bonds, and the innovative tokenization projects in Singapore's private funds and credit sectors. Mr. Ma also addressed the existing challenges such as achieving interoperability among private blockchains operated by large financial institutions, creating unified technical standards, and the critical need for establishing more compliant and secure trading platforms. The platform gathers asset owners, brokers, investors, and well-known FinTech companies from the Asia Pacific region, aiming to: Develop an RWA ecosystem that enables seamless information exchange between recognized asset tokenization participants and traditional institutions. Establish standardized tokenization procedures and protocols across different asset categories. Construct reliable and secure blockchain infrastructure. Promote practical applications and business cases for asset tokenization, as well as improve legal compliance and ethical standards. Representatives from ChainUp, Alibaba Cloud, and the Blockchain Association, reflecting their unique perspectives on the summit's theme and their company's attributes: ChainUp CEO Sailor Zhong stated, "Blockchain technology is redefining the frontiers of traditional finance. Our innovative technology and services lay the groundwork for the tokenization of RWAs, enhancing the transparency and efficiency of transactions." The Alibaba Cloud representative mentioned, "As a leading global cloud service provider, we are confident in supporting APRTP by offering a secure, stable, and efficient cloud computing platform for the tokenization of RWAs." The Blockchain Association representative emphasized, "We are committed to promoting the growth and regulation of the blockchain industry. We support APRTP in setting tokenization standards and ethical guidelines to ensure the industry develops in a healthy and stable manner." The Asia Pacific region has long been a global leader in dynamism, growth, and innovation in finance, technology, and green development. With the formation of APRTP, there is an intention to collaborate with industry leaders to deepen innovation and compliance within the region, setting international standards and aspiring to become the global leader in the RWA field. The members believe that through strengthened cooperation and shared knowledge and experience, they can significantly contribute to the future development of the RWAs tokenization domain. Contact: Info@aprtp.comWebsite: www.aprtp.comLinkedin: https://www.linkedin.com/company/ap-r-tp/
SINGAPORE - Media OutReach - 23 November 2023 - Lendela, the digital loan matchmaking platform, announced today its successful $US5M Series A funding round. The oversubscribed round was led by Singapore-based Chocolate Ventures, with participation from Lendela’s seed investor Cocoon Capital. The round was also joined by Phillip Private Equity and Genting Ventures, propelling Lendela's commitment to democratise personal loans. Lendela was founded in 2018 with a mission to simplify and streamline the personal loan application process. The platform empowers borrowers with transparent and personalised loan options, offering a refreshing alternative to the traditional labyrinth of the current lending landscape. Founder and CEO Nima Karimi said, "The personal loan journey is often complex and unnerving for the borrower. Consumers deserve clarity and choice when making critical loan decisions. That has always been Lendela’s goal.” Empowering borrowers with clarity and choice Unlike the convoluted and often opaque lending landscape, Lendela stands out as a beacon of simplicity and transparency. "Our platform increases access to the most affordable and realistic credit options available, taking into account each profile’s credit history. We aim to transform the borrower experience, making it easier for individuals to make informed decisions about their loans”, Karimi explained. Over the years, Lendela has achieved remarkable milestones. These include achieving profitability in its core markets, doubling its business annually, and pioneering lightning-fast loan processing times from application to money in the account in as quick as 10 minutes, owing to API integrations with lending partners and government-accredited open banking ecosystems. Lendela's commitment to providing a superior borrowing experience is evident in its extensive track record. In the last year alone, the fintech has brought over USD 3.7m in savings to borrowers thanks to its unique reverse auction model. Their extensive network of lenders also ensures that borrowers have access to a wide array of loan options, regardless of credit and transactional profiles. Charting a path forward Notable lead investors from Lendela’s Series A round include Cocoon Capital and Chocolate Ventures. Chocolate Ventures was started by Singlife founder and former Group Chief Executive, Walter de Oude, who recognised the pressing need for enhanced options and transparency in financial services. De Oude emphasised that “Businesses that add real value to customers are businesses that will last. Consumer finance is a necessary part of so many lives, and making lending more democratic is a meaningful endeavour. Lendela is well loved by the customers it services and will grow as a result. I love businesses that really add value to everyday people and make people's lives better.” Looking ahead, Lendela plans to expand across the Asia-Pacific region, following its launch in Australia earlier this year. Additionally, the funds will be directed toward product development to enhance integration and broaden the scope of consumer services benefiting from greater transparency. "We are not disruptors - we are enablers. Our platform connects consumers with the best loan providers, streamlining the process for greater efficiency so nobody pays more than necessary for their loan", said Karimi. Hashtag: #Lendelahttps://hk.lendela.com/https://www.linkedin.com/company/lendelahttps://www.facebook.com/lendelaHKhttps://www.instagram.com/lendelahk/The issuer is solely responsible for the content of this announcement.ABOUT LENDELA PTE. LTD. Founded in Singapore, Lendela is Asia-Pacific’s leading digital loan matchmaker connecting borrowers with their most accurate loan options. Driven by our mission to democratise personal loans, Lendela helps consumers navigate their loan journey with ease by harmonising the interests of lenders and borrowers. Since our inception in 2018, Lendela has empowered over 100,000 consumers with clarity and confidence to make informed loan decisions with an extensive range of choice from more than 100 lending partners. Today, Lendela serves customers in three markets with offices in Singapore, Hong Kong, Sydney and Kuala Lumpur.
ROCKVILLE, Md. and SUZHOU, China, Nov. 23, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, and AnHeart Therapeutics ("AnHeart"), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, announce that the New Drug Application (NDA) for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. The NDA acceptance are based on positive results from the Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated taletrectinib in Chinese ROS1-positive NSCLC patients. Results from an interim analysis of the TRUST-I trial were presented at the European Lung Cancer Congress (ELCC) 2023.[Link] Professor Caicun Zhou, Principal Investigator and Oncologist at Shanghai Pulmonary Hospital, stated: "We have extremely limited options for our patients with ROS1-positive NSCLC, especially those with brain metastases who represent more than one-third of patients, and those who go on to develop resistant mutations, which is more than half of patients. Once patients progress on the current options, there are no approved treatments. I hope this NDA represents a step towards making another option available to the ROS1-positive NSCLC patient community in China." Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are encouraged by the best-in-class efficacy and safety profile that taletrectinib demonstrated in the TRUST-I trial, and are excited about the NDA acceptance in China. Together with our partner AnHeart, we will work closely with the NMPA to bring this precision therapy to NSCLC patients who are in need of novel treatment options, especially those with acquired resistant mutations or with brain metastases." Bing Yan, MD, Chief Medical Officer of AnHeart, stated: "Acceptance of our China NDA marks an important milestone for AnHeart and is the first regulatory submission for taletrectinib globally. We would like to thank all the doctors and patients who participated in the clinical trials that support this submission. We look forward to working with our partner Innovent and the regulatory authorities in China to hopefully make taletrectinib available to patients in need as soon as possible." In June 2021, Innovent and AnHeart entered into an exclusive license agreement for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau and Taiwan. About ROS1-positive Non-small Cell Lung Cancer More than one million people globally are diagnosed with NSCLC annually, the most common form of lung cancer. It is estimated that approximately 3% of people with NSCLC in China are ROS1-positive. There are approved first-generation TKIs for people with newly diagnosed advanced or metastatic ROS1-positive NSCLC and no approved therapies for people whose ROS1-positive NSCLC has progressed following treatment with these medicines. Up to 35% of people newly diagnosed with metastatic ROS1-positive NSCLC have tumors that have spread to their brain (brain metastases), the number increases to approximately 55% for those whose cancer has progressed following initial treatment. About Taletrectinib Taletrectinib is an oral, potent, brain penetrant, selective, next-generation potential best-in-class ROS1 inhibitor being evaluated for the treatment of ROS1-positive NSCLC. Taletrectinib was evaluated in ROS1-positive NSCLC patients in two Phase 2 trials, TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global pivotal trial. Positive interim results from TRUST-II trial were reported at the ELCC 2023, and positive interim results from TRUST-II trial were reported at the European Society of Medical Oncology Congress 2023.[Link] Taletrectinib was granted Breakthrough Therapy Designation (BTD) by the CDE of NMPA in 2022 for the treatment of adult patients with advanced or metastatic ROS1-positive NSCLC who have previously been treated with a ROS1 TKI as well as those who have not previously been treated by a ROS1 TKI (TKI-naïve). In addition, taletrectinib has also been granted BTD for the treatment of ROS1-positive NSCLC by the U.S. Food and Drug Administration in the United States in 2022. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene Autoleucel Injection) and SINTBILO® (Tafolecimab Injection). Additionally, we have 1 NDA under NMPA review, 6 assets in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage. Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. Note: TYVYT® (sintilimab injection) is not an approved product in the United States. BYVASDA® (bevacizumab biosimilar injection), SULINNO®, and HALPRYZA® (rituximab biosimilar injection) are not approved products in the United States. TYVYT® (sintilimab injection, Innovent) BYVASDA® (bevacizumab biosimilar injection, Innovent) HALPRYZA® (rituximab biosimilar injection, Innovent) SULINNO® (adalimumab biosimilar injection, Innovent) Pemazyre® (pemigatinib oral inhibitor, Incyte Corporation). Pemazyre® was discovered by Incyte Corporation and licensed to Innovent for development and commercialization in Mainland China, Hong Kong, Macau and Taiwan. CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Disclaimer: Innovent does not recommend any off-label usage. About AnHeart Therapeutics AnHeart Therapeutics ("AnHeart'') is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. Our lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. Food and Drug Administration and the China National Medical Products Administration. AnHeart's second investigational therapy, safusidenib, is a mIDH1-inhibitor being evaluated in a Phase 2 trial for IDH1-mutant glioma. Our mission is to improve the lives of people with cancer. We are supported by leading life sciences investors and have built an organization with deep oncology drug discovery and development expertise, with offices in New York and Shanghai. For more information, visit https://www.anhearttherapeutics.com/ or follow us on LinkedIn at https://www.linkedin.com/company/anheart-therapeutics-official/. Innovent's Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Hyundai Motor and UCL sign a memorandum of understanding (MOU) ahead of the UK-Korea Business Forum in London on November 22 with key leaders attending Hyundai Motor and UCL to conduct joint research on hydrogen production, fuel cells and electrification technologies, leveraging UCL's new Advanced Propulsion Lab Both parties look to achieve carbon neutrality by accelerating the establishment of a hydrogen economy and realizing a sustainable future mobility ecosystem SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ -- Hyundai Motor Company today announced that it is partnering with the world-renowned University College London (UCL) to jointly research carbon-neutral future technologies. (From left) Kemi Badenoch, Secretary of State for Trade and Business; Angharad Milenkovic, Vice-President (Advancement) UCL; Professor Nigel Titchener-Hooker, Dean of Engineering Sciences, UCL; Dr Michael Spence, President and Provost, UCL; Dongwook Kim, Executive Vice President, HMC; Moonkyu Bang, Minister of Trade, Industry and Energy of the Republic of Korea. Hyundai Motor signed a memorandum of understanding (MOU) on 'Cooperation in areas of Research and Development for Hydrogen Production, Hydrogen Fuel Cells and Electrification Technology' with UCL at Mansion House in London on November 22. The MOU signing ceremony took place prior to the UK-Korea Business Forum. In attendance were government officials from both countries, including Moon-kyu Bang, South Korea's Minister of Trade, Industry and Energy; and Nigel Huddleston, UK Secretary of State for International Trade; as well as Dong-wook Kim, Executive Vice President of Hyundai Motor Company; and Dr Michael Spence, President and Provost of UCL. With both South Korea and UK aiming to achieve carbon neutrality by 2050, Hyundai Motor looks to accelerate the development of a hydrogen economy and realize a sustainable future mobility ecosystem through this MOU. UCL is a prestigious research-oriented university that is consistently ranked at the top of global university rankings and has produced dozens of Nobel Prize and Fields Medal winners. "Through joint research with UCL, one of the UK's leading research universities, we will accelerate the pace of technological innovation in hydrogen production, fuel cells and electrification," said Jaehoon (Jay) Chang, President and CEO of Hyundai Motor Company. "We hope that this collaboration will contribute to achieving carbon neutrality in the transportation sector, which is a goal shared by Korea and the UK." UCL President and Provost, Dr Michael Spence said, "New technologies, such as hydrogen generation, electric vehicles and fuel cells, are a fundamental part of international efforts to keep the global temperature rise within the goals set out in the Paris Agreement. This partnership will combine UCL's world-leading engineering research with Hyundai's expertise as one of the world's leading automotive companies to accelerate the development of these vital technologies."
A12 藝術空間
business
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
